^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + eprenetapopt (APR-246) (p53 reactivator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
516MO - Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies
Published date:
09/13/2021
Excerpt:
A safety lead-in with a 3+3 dose de-escalation design for patients (pts) with advanced solid tumors with known tumor TP53 mutation status...The dose of eprenetapopt of 4.5 g/day IV D1-4 and pembrolizumab 200mg IV D3 Q3W was established as the RP2D...Two pts with TP53 mutant NSCLC who received prior anti-PD-1/PD-L1 therapy demonstrated reductions in target lesion size of 27% and 8.2%, respectively...
Trial ID:
